White Paper: Risky Business

How the proliferation of quality system audits threatens to cripple cell collection site capacity

Contact our team to start building your solution

While recent therapeutic advancements in cell and gene therapy present hope for many patients, the rapid proliferation of these therapies is putting substantial stress on cell collection and processing sites. Left unaddressed, current processes risk overwhelming this infrastructure and ultimately delaying the delivery of time-sensitive therapies to patients.

Learn more in our white paper, “Risky Business: How the proliferation of quality system audits threatens to cripple cell collection site capacity,” authored by Heather Steinmetz, MPH, Quality Assurance Manager, UCLA Health Hematologic Malignancy/Stem Cell Transplant Program; Amy Hines, RN, BSN, director, Collection Network Management, Be The Match BioTherapies and Richard Smith, consultant, Be The Match BioTherapies.

Download the white paper